Abstract 177P
Background
Stomach cancer (SC) ranks as the 3rd leading cause of death among all cancer-related fatalities in the South Asia (SA) region. The complex interplay of cultural, lifestyle, and demographic factors in SA compounds the challenge to public health posed by the significant burden of stomach cancer.
Methods
Using the Global Burden of Disease framework, this study examined deaths and disability-adjusted life years (DALYs) attributed to SC caused by smoking by age, sex, and year across the 5 countries of the SA region from 1990-2019. Additionally, projections for the number of deaths up to 2040 were derived through regression analysis.
Results
The total count of deaths attributed to SC due to smoking witnessed an increase from 6,948 (95%UI: 4,963-8,890) in 1990 to 9,353 (95%UI: 6,632-12,325) in 2019. Concurrently, DALYs rose from 177,675 (95%UI: 124,165-232,327) in 1990 to 222,290 (95%UI: 149,831-299,787) in 2019. Assessing the annual percentage of change (APC), the Age-Standardized Mortality Rate (ASMR) experienced a decline of 49% from 1990-2019. Among the SA countries, Nepal exhibited the highest APC increase in total deaths at 76%, followed by Bhutan at 73%, India at 40%, Pakistan at 20%, and Bangladesh at 13% from 1990-2019. Conversely, the APC increase in DALYs was greatest in Nepal at 51%, while Bangladesh reported the lowest increase at 3% during the same period. Notably, the age group of 65-69 years recorded the highest number of deaths (1,555), while the age group of 60-64 years experienced the highest DALYs (37,194) in 2019. In terms of gender disparities, males bore a higher burden of stomach cancer attributable to smoking compared to females over the past three decades. The study's projections indicate an estimated 3,952 deaths (95%UI: 2,036-6,347) by the year 2040.
Conclusions
While notable advancements have been made in the management of SC, the burden attributed to smoking continues to rise over the last 3 decades. This accounts for 9.44% of deaths among the overall causes of SC-related fatalities. It emphasizes the importance of comprehensive tobacco control strategies to mitigate this burden, considering the diverse social, economic, and cultural factors unique to the region.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
602P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma
Presenter: Andrew Haydon
Session: Poster Display
Resources:
Abstract
603P - An individualised postoperative radiological surveillance schedule for IDH-wildtype glioblastoma patients (HK-GBM Registry)
Presenter: Jason Chak Yan Li
Session: Poster Display
Resources:
Abstract
604P - Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status
Presenter: Marcia Brose
Session: Poster Display
Resources:
Abstract
606P - BRAF and NRAS mutations are associated with poor prognosis in Asians with acral-lentiginous and nodular cutaneous melanoma
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract
607P - Single institutional outcomes of radiotherapy and systemic therapy for melanoma brain metastases in Japan
Presenter: Naoya Yamazaki
Session: Poster Display
Resources:
Abstract
608P - The efficacy of immune checkpoint inhibitors and targeted therapy in mucosal melanomas: A systematic review and meta-analysis
Presenter: Andrea Teo
Session: Poster Display
Resources:
Abstract
609P - The association between thyroid function abnormalities and vitiligo induced by pembrolizumab regarding prognosis in patients with advanced melanoma
Presenter: Moez Mobarek
Session: Poster Display
Resources:
Abstract
610P - Analyzing the clinical benefit of the evidence presented at these congresses and utilizing a standardized scale to quantify it will significantly enhance our understanding of the studies showcased, allowing for more objective evaluation and interpretation
Presenter: Charles Jeffrey Tan
Session: Poster Display
Resources:
Abstract
611P - ESMO-magnitude of clinical benefit scale (MCBS) scores for phase III trials of adjuvant and curative therapies at the 2022 ASCO annual meeting (ASCO22)
Presenter: Thi Thao Vi Luong
Session: Poster Display
Resources:
Abstract
612P - Is the juice worth the squeeze? Overall survival gain per unit treatment time as a metric of clinical benefit of systemic treatment in incurable cancers
Presenter: Vodathi Bamunuarachchi
Session: Poster Display
Resources:
Abstract